DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020766/S-029

SUPPLEMENT APPROVAL

Hoffmann-La Roche, Inc.
Attention: Margaret J. Jack
Director, Pharma Development Regulatory
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Ms. Jack:

Please refer to your Supplemental New Drug Application (sNDA) dated June 30, 2010, received July 2, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Xenical (orlistat) Capsules, 120 mg.

We acknowledge receipt of your amendment dated February 4, 2011. We also acknowledge receipt of your email dated January 18, 2012, stating your agreement to the labeling revisions that we communicated to you by email on January 16, 2012.

This "Prior Approval" supplemental new drug application provides for the following labeling changes:

1. Addition of "Pregnancy" to the CONTRAINDICATIONS section and revision of the Pregnancy Category from (b) (4) to "X."
2. Addition of information describing cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure while taking Xenical to the WARNINGS AND PRECAUTIONS section.
3. Revision of the time to administer cyclosporine to three hours after Xenical in patients receiving both Xenical and cyclosporine therapy.
4. Conversion of the format to comply with the Physician's Labeling Rule (PLR).

prior labels have "B" category

We have completed our review of this supplemental application, as amended. It is **approved**, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content

of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We request that for a period of two years, you submit all reported cases of gastrointestinal bleeding as 15-day alert reports. We request that you attempt to gather the following additional information on these cases: INR, CBC, PT, PTT, coagulation defects including vitamin K deficiency; resuscitation measures, including blood transfusion; results of endoscopy, colonoscopy, or other diagnostic work-up procedures; and duration of treatment with orlistat.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Patricia Madara, Regulatory Project Manager, at (301) 796-1249.

Sincerely,

{See appended electronic signature page}

Eric Colman, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC C COLMAN
01/20/2012